SCHEMBL807124

SCHEMBL807124

CNC1(C(N)=O)CCNCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 1.00
KMT2A Q03164 1/20 1.00
CYP1A2 P05177 1/20 0.33
PKM P14618 1/20 0.32
EPHX1 P07099 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31297979 0.88 KDM4E (0.78) KDM4EKMT2APKM
SCHEMBL3715654 0.84
SCHEMBL16750982 0.82 KDM4E (0.69) KDM4EKMT2ACYP1A2
SCHEMBL6867738 0.80 KDM4E (0.67) KDM4EKMT2ACYP1A2
SCHEMBL14533055 0.79
SCHEMBL13448658 0.79 KDM4E (0.65) KDM4EKMT2ACYP1A2PKM
SCHEMBL18012255 0.78 KDM4E (0.64) KDM4EKMT2ACYP1A2
SCHEMBL971440 0.78 KDM4E (0.63) KDM4EKMT2ACYP1A2
SCHEMBL5240027 0.78 KDM4E (0.63) KDM4EKMT2ACYP1A2
SCHEMBL18122821 0.77 KDM4E (0.63) KDM4EKMT2ACYP1A2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250043353-A1 BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE MILLENNIUM PHARM INC (US) 2025-02-06 US disclosed
EP-3515916-B1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2023-06-07 EP disclosed
CN-106458992-B Pyridyl piperidine 默克专利股份公司 2019-03-15 CN disclosed
EP-3122739-B1 PYRIDYL PIPERIDINES MERCK PATENT GMBH (DE) 2019-01-16 EP disclosed
EP-3122739-B1 PYRIDYL PIPERIDINES MERCK PATENT GMBH (DE) 2019-01-16 EP disclosed
US-9926319-B2 Pyridyl piperidines MERCK PATENT GMBH (DE) 2018-03-27 US disclosed
US-9926319-B2 Pyridyl piperidines MERCK PATENT GMBH (DE) 2018-03-27 US disclosed
US-20170107222-A1 PYRIDYL PIPERIDINES MERCK PATENT GMBH (DE) 2017-04-20 US disclosed
US-20170107222-A1 PYRIDYL PIPERIDINES MERCK PATENT GMBH (DE) 2017-04-20 US disclosed
EP-2078003-B1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME (US) 2017-03-08 EP disclosed
EP-1558615-B1 PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS PFIZER PROD INC (US) 2007-08-29 EP disclosed
US-20070161570-A1 Methionine aminopeptidase-2 inhibitors and methods of use thereof PRAECIS PHARMACEUTICALS, INC. (US) 2007-07-12 US disclosed
CN-1914182-A Quinazoline derivatives ASTRAZENECA AB (SE) 2007-02-14 CN disclosed
US-20070010452-A1 Methionine aminopeptidase-2 inhibitors and methods of use thereof PRAECIS PHARMACEUTICALS, INC. (US) 2007-01-11 US disclosed
US-7157420-B2 Therapeutic agents and methods of use thereof for the modulation of angiogenesis PRAECIS PHARMACEUTICALS, INC. (US) 2007-01-02 US disclosed
EP-1713781-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2006-10-25 EP disclosed
WO-2005075439-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2005-08-18 WO disclosed
EP-0808303-B1 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST ASTRAZENECA AB (SE) 2001-06-20 EP disclosed
EP-0808303-A1 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST ZENECA LIMITED (GB) 1997-11-26 EP disclosed
WO-1996024582-A1 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST ZENECA LIMITED (GB) 1996-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010452-A1 Methionine aminopeptidase-2 inhibitors and methods of use thereof METAP2, METAP1, DNPEP KDM4E 1216/4885KMT2A 446/4885CYP1A2 1321/4885
US-20250043353-A1 BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE WNT1, XPOT, CTNNBL1 KDM4E 2279/4885KMT2A 598/4885CYP1A2 3868/4885
US-20070161570-A1 Methionine aminopeptidase-2 inhibitors and methods of use thereof METAP2, METAP1, LNPEP KDM4E 1741/4885KMT2A 1477/4885CYP1A2 2238/4885
US-20170107222-A1 PYRIDYL PIPERIDINES WNT1, CTNNB1, WNT3 KDM4E 1124/4885KMT2A 2950/4885CYP1A2 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.